Apellis Pharmaceuticals Inc (NQ: APLS )

44.26 USD -1.38 (-3.02%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2021 Add to My Watchlist

Price and Volume

Volume	1,205,455
Open	45.39
Bid (Size)	49.00 (1)
Ask (Size)	49.80 (2)
Prev. Close	45.64
Today's Range	43.57 - 46.83
52wk Range	25.49 - 58.47
Shares Outstanding	80,496,771
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Today 18:25 EDT

Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

May 12, 2021

Performance

YTD	-18.92%	-18.92%
1 Month	-0.49%	-0.49%
3 Month	-5.12%	-5.12%
6 Month	+14.28%	+14.28%
1 Year	+45.88%	+45.88%

More News

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 07, 2021

Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results

April 28, 2021

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

April 26, 2021

Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021

April 21, 2021

Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 16, 2021

Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy

April 13, 2021

The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH

March 17, 2021

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

March 17, 2021

Notable Thursday Option Activity: GILD, APLS, ESI

April 29, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.